Monday, January 11, 2021 11:08:32 PM
Shuman Glenn
1:31 PM ET 1/11/21 | BusinessWire
DENVER--(BUSINESS WIRE)--January 11, 2021--
Shuman Glenn & Stecker announces that it is investigating potential shareholder claims against certain officers and directors of Acadia Pharmaceuticals, Inc. ("Acadia" or the "Company") (NYSE: ACAD). Acadia is a biopharmaceutical company focusing on the development and commercialization of medicines to address central nervous system disorders. The Company's lead drug, NUPLAZID, was approved in 2016 by the U.S. Food and Drug Administration ("FDA") for treatment of hallucinations and delusions associated with Parkinson's disease psychosis.
The Firm's investigation relates to allegations in a securities fraud class action lawsuit against Acadia and certain of its senior officers in the U.S. District Court for the Southern District of California. The lawsuit alleges that the defendants failed to publicly disclose material facts, including: (i) adverse events, safety concerns, and mounting reports of deaths related to NUPLAZID post-commercialization, which raised the risk that the FDA would reconsider its approval of NUPLAZID and/or that industry watchdogs would warn against prescribing NUPLAZID; (ii) that Acadia undertook a campaign to pay off physicians to prescribe NUPLAZID; and (iii) that Acadia's improper business practices exposed the Company to potential regulatory scrutiny. In a June 1, 2020 ruling denying in part the motion to dismiss the lawsuit, the federal judge determined that it had been sufficiently alleged that the defendants did not properly disclose the high mortality rate during testing for NUPLAZID or the payments of kickbacks to doctors who prescribed NUPLAZID.
On April 9, 2018, following a CNN report about mounting deaths associated with NUPLAZID, Acadia's stock price fell by over 23% to close at $16.50 per share. After CNN subsequently reported on April 25, 2018 that the FDA was re-examining the safety of NUPLAZID, Acadia's stock price fell again, by nearly 22% to close at $15.20 per share.
If you currently own Acadia common stock and are interested in discussing your rights, or have information relating to this investigation, please contact Kip Shuman toll free at (866) 569-4531 or email Mr. Shuman at kip@shumanlawfirm.com.
Shuman Glenn & Stecker represents investors throughout the nation, concentrating its practice in stockholder litigation.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210111005918/en/
CONTACT: SHUMAN GLENN & STECKER
Kip B. Shuman, Esq.
100 Pine Street, Suite 1250
San Francisco, CA 94111
Tel: 866.569.4531
Fax: 303.536.7849
Email: kip@shumanlawfirm.com
Web: www.shumanlawfirm.com
SOURCE: Shuman Glenn & Stecker
Copyright Business Wire 2021
> Dow Jones Newswires
January 11, 2021 13:31 ET (18:31 GMT)
Recent ACAD News
- Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences • Business Wire • 08/28/2024 08:05:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/20/2024 10:46:23 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/20/2024 10:43:23 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/20/2024 10:40:42 PM
- Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments • Edgar (US Regulatory) • 08/20/2024 08:39:26 PM
- Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments • Edgar (US Regulatory) • 08/20/2024 08:37:56 PM
- Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments • Edgar (US Regulatory) • 08/20/2024 08:35:57 PM
- Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments • Edgar (US Regulatory) • 08/20/2024 08:33:27 PM
- Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments • Edgar (US Regulatory) • 08/20/2024 08:31:27 PM
- Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments • Edgar (US Regulatory) • 08/20/2024 08:29:57 PM
- Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments • Edgar (US Regulatory) • 08/20/2024 08:27:51 PM
- Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments • Edgar (US Regulatory) • 08/20/2024 08:25:57 PM
- Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments • Edgar (US Regulatory) • 08/20/2024 08:23:55 PM
- Ryan Reynolds Announces More to Parkinson’s® Campaign • Business Wire • 08/14/2024 12:04:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/13/2024 10:05:04 PM
- Acadia Pharmaceuticals to Participate in the Canaccord Genuity 44th Annual Growth Conference • Business Wire • 08/07/2024 08:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/06/2024 08:13:44 PM
- Acadia Pharmaceuticals Reports Second Quarter 2024 Financial Results and Operating Overview • Business Wire • 08/06/2024 08:05:00 PM
- Acadia Pharmaceuticals to Announce Second Quarter Financial Results on August 6, 2024 • Business Wire • 07/24/2024 08:05:00 PM
- Clinical Data from Open-Label Extension LILAC-1™ and LILAC-2™ Studies Evaluating Long-Term Safety and Efficacy of DAYBUE™ (trofinetide) in Patients with Rett Syndrome Published in Med • Business Wire • 07/18/2024 01:04:00 PM
- Acadia Pharmaceuticals Presents DAYBUE™ (trofinetide) Real-World Evidence and Additional Data in Rett Syndrome at the 2024 International Rett Syndrome Foundation (IRSF) Annual Scientific Meeting • Business Wire • 06/18/2024 01:04:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/11/2024 10:00:05 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/31/2024 10:00:21 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/31/2024 10:00:18 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/31/2024 10:00:16 PM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM